The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests. This finalized rate represents an increase from the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Obtaining the final rate represents a positive development and will be e

Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are two underdiagnosed, potentially fatal forms of heart disease that standard diagnostic testing routinely fails to detect Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered Precision Cardiovascular Medicine company, today announced that the Company will be presenting new data at the American Heart Association (AHA) Scientific Sessions demonstrating that the epigenetic biomarkers of the Company's PrecisionCHD test are able to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (

A customized program for YMCA of East Tennessee members will include educational series "Wisdom Wednesdays," and access to Cardio Diagnostics' AI-powered cardiovascular testing at discounted rates from home or during the Heart Health Fair Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Company is partnering with YMCA of East Tennessee to launch a customized program exclusively for its members. Through this program, YMCA members will learn how to take proactive steps to prevent and detect heart disease early while gaining access to Epi+Gen CHD™ and PrecisionCHD™ clinical tests from Cardio Diagnostics at a sp

Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care Practices Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the United States. This expansion demonstrates the continued adoption of the Company's innovative blood tests, Epi+Gen CHD™ and PrecisionCHD™, which are transforming the prevention, detection, and management of coronary heart disease across diverse clinical settings. The new provider organizations represent various medical specialties and care models, spanning four maj

Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS), through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. A ‘gapfill' payment rate means that pricing is determined by each Medicare contractor, including MolDX, based on cost data from Cardio Diagnostics. These preliminary payment rates, proposed as part of the calendar year 2025 gapfill pricing process, are expected to be finalized later t

AGEPHA Pharma will supply LODOCO® (low-dose colchicine) for a Cardio Diagnostics-sponsored clinical study to explore the use of Cardio Diagnostics' PrecisionCHD™ test to identify patients with inflammation-driven coronary heart disease (CHD) Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a precision cardiovascular medicine company with a pioneering technology at the intersection of epigenetics and AI, today announced an agreement with AGEPHA Pharma that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease (CHD). Specifically, AGEPHA Pharma will supply LODOCO® (low-dose colchicine), its FDA-approved anti-inflammatory medication,

Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's intellectual property portfolio. The patent, titled "Compositions and Methods for Detecting Predisposition to Cardiovascular Disease," (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics' founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors. The Japanese patent further strengthen

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a pioneer in AI-powered precision cardiovascular medicine, today announced that on May 28, 2025, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Requirement") for continued listing on The Nasdaq Capital Market. This was disclosed in the Company's Current Report on Form 8-K filed on May 28, 2025. The Nasdaq staff made this determination of compliance af

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a pioneer in AI-powered precision cardiovascular medicine, today announced the continued expansion of its reach with a new cohort of healthcare practices across the United States now offering its innovative clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™. This group of adopters spans a wide range of care models - from concierge and direct primary care to functional and integrative medicine, demonstrating the growing appetite for proactive, personalized cardiovascular care. These latest adopters are primarily independent practices deeply committed to modernizing the patient experience and championing heart disease prevention and early d

Cardio Diagnostics Holdings, Inc. ("Cardio" or the "Company") (NASDAQ:CDIO), today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025. The reverse stock split will take effect at 11:59 pm Eastern Time on May 12, 2025, and the Company's common stock will open for trading on The Nasdaq Capital Market on May 13, 2025 on a post-split basis, under the existing ticker symbol "CDIO" but with new CUSIP number 14159C202. The reverse stock split is part of the Company's plan to regain compliance with the minimum bid price requirement for the continued listing on The Nasdaq Capital Market. The reverse split was authorized by the Company's s

4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

424B3 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

EFFECT - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

POS AM - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

EFFECT - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

POS AM - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

DEFA14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

DEF 14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical

SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)